Posted by Michael Wonder on 08 Apr 2026
Ray Therapeutics receives FDA regenerative medicine advanced therapy designation for RTx-015 in retinitis pigmentosa
1 April 2026 - Ray Therapeutics today announced that the US FDA has granted regenerative medicine advanced therapy designation to its lead candidate, RTx-015, for the treatment of retinitis pigmentosa.
RTx-015 is Ray Therapeutics’ lead optogenetic gene therapy currently being evaluated in patients with retinitis pigmentosa.
